AKAO 2017 Annual Report

81 Part II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. Our common stock has been listed on the Nasdaq Global Market under the symbol “AKAO” since March 12, 2014. Prior to that date, there was no public trading market for our common stock. The following table details the high and low intraday sales prices for our common stock for the periods indicated as reported by the Nasdaq Global Market for AKAO. Price Range Fiscal year ended December 31, 2017 High Low 1st Quarter .......................................................................................................... $ 27.79 $ 12.33 2nd Quarter ......................................................................................................... $ 27.49 $ 19.50 3rd Quarter.......................................................................................................... $ 25.22 $ 15.16 4th Quarter .......................................................................................................... $ 16.40 $ 10.24 Fiscal year ended December 31, 2016 1st Quarter .......................................................................................................... $ 5.95 $ 2.59 2nd Quarter ......................................................................................................... $ 6.08 $ 2.60 3rd Quarter.......................................................................................................... $ 5.22 $ 3.36 4th Quarter .......................................................................................................... $ 16.20 $ 3.68 On February 26, 2018, the last trading day prior to February 27, 2018, the closing price for our common stock as reported by the Nasdaq Global Market was $11.06. Performance Graph This graph is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference into any filing of Achaogen, Inc. under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. The graph below compares our total stock return with the total return for the NASDAQ Composite Index and the NASDAQ Biotechnology Index for the period from March 12, 2014 (the first day of trading of our common stock) through December 31, 2017 The graph shows the performance of a $100 investment in our common stock and in each index (with the reinvestment of all dividends) at market close on March 12, 2014 (the first day of trading of our common stock) through December 31, 2017. Pursuant to applicable Securities and Exchange Commission rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our common stock to date. Historical stockholder return is not necessarily indicative of the performance to be expected for any future periods and we do not make or endorse any predictions as to future stockholder returns.